Investment Considerations InMed has a world class leadership team with a successful track record of drug development and commercialization. InMed has a solid and expanding intellectual property portfolio with multiple patents filed. The company recently acquired rare cannabinoids manufacturer BayMedica. InMed retains all commercial rights to its IntegraSyn manufacturing system. InMed has commenced a Phase … Continue reading “InMed Pharmaceuticals Inc. (NASDAQ: INM)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |